CDKL5 and acute myeloid leukemia: KSEA analysis showed that, similar to the results in cell lines, PF-3758309 directly reduced the activity of PAK1 (PDTs), PAK2 (Signor) and PAK4 (PDTs) in AML primary cells and indirectly targeted the kinase CDKL5 that is also involved in cytoskeletal reorganization [29].